An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection by Akram, K M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus
infection
Akram, K M; Moyo, N A; Leeming, G H; Bingle, L; Jasim, S; Hussain, S; Schorlemmer, A; Kipar, A;
Digard, P; Tripp, R A; Shohet, R V; Bingle, C D; Stewart, J P
Abstract: The airway epithelium secretes proteins that function in innate defense against infection.
Bactericidal/permeability-increasing fold-containing family member A1 (BPIFA1) is secreted into airways
and has a protective role during bacterial infections, but it is not known whether it also has an antiviral
role. To determine a role in host defense against influenza A virus (IAV) infection and to find the
underlying defense mechanism, we developed transgenic mouse models that are deficient in BPIFA1 and
used these, in combination with in vitro three-dimensional mouse tracheal epithelial cell (mTEC) cultures,
to investigate its antiviral properties. We show that BPIFA1 has a significant role in mucosal defense
against IAV infection. BPIFA1 secretion was highly modulated after IAV infection. Mice deficient in
BPIFA1 lost more weight after infection, supported a higher viral load and virus reached the peripheral
lung earlier, indicative of a defect in the control of infection. Further analysis using mTEC cultures
showed that BPIFA1-deficient cells bound more virus particles, displayed increased nuclear import of
IAV ribonucleoprotein complexes, and supported higher levels of viral replication. Our results identify a
critical role of BPIFA1 in the initial phase of infection by inhibiting the binding and entry of IAV into
airway epithelial cells.
DOI: https://doi.org/10.1038/mi.2017.45
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-145019
Published Version
 
 
Originally published at:
Akram, K M; Moyo, N A; Leeming, G H; Bingle, L; Jasim, S; Hussain, S; Schorlemmer, A; Kipar, A;
Digard, P; Tripp, R A; Shohet, R V; Bingle, C D; Stewart, J P (2018). An innate defense peptide
BPIFA1/SPLUNC1 restricts influenza A virus infection. Mucosal Immunology, 11(1):71-81.
DOI: https://doi.org/10.1038/mi.2017.45
OPEN
An innate defense peptide BPIFA1/SPLUNC1
restricts influenza A virus infection
KMAkram1,9, NAMoyo2,9, GHLeeming2,3, L Bingle4, S Jasim5, SHussain5, A Schorlemmer6, AKipar2,3,7,
P Digard5, RA Tripp8, RV Shohet6, CD Bingle1,10 and JP Stewart2,10
The airway epithelium secretes proteins that function in innate defense against infection. Bactericidal/permeability-
increasing fold-containing family member A1 (BPIFA1) is secreted into airways and has a protective role during bacterial
infections,but it isnotknownwhether it alsohasanantiviral role.Todeterminea role inhostdefenseagainst influenzaAvirus
(IAV) infection and to find the underlying defensemechanism, we developed transgenicmousemodels that are deficient in
BPIFA1 and used these, in combination with in vitro three-dimensional mouse tracheal epithelial cell (mTEC) cultures, to
investigate its antiviral properties. We show that BPIFA1 has a significant role in mucosal defense against IAV infection.
BPIFA1 secretion was highly modulated after IAV infection. Mice deficient in BPIFA1 lost more weight after infection,
supported a higher viral load and virus reached the peripheral lung earlier, indicative of a defect in the control of infection.
Further analysis usingmTEC cultures showed that BPIFA1-deficient cells boundmore virus particles, displayed increased
nuclear import of IAV ribonucleoprotein complexes, and supported higher levels of viral replication. Our results identify a
critical role of BPIFA1 in the initial phase of infection by inhibiting the binding and entry of IAV into airway epithelial cells.
INTRODUCTION
The airway epithelium has a fundamental role in the initial
defense against pathogens and as such secretes a number of
proteins/peptides that function in innate defense.1 Bactericidal/
permeability-increasing fold-containing family A1 (BPIFA1;
also called SPLUNC1) is a glycoprotein that is highly expressed
in the respiratory epithelium and submucosal glands of the
upper airways in mice and humans.2–9 The mouse and human
BPIFA1 sequences are homologous.8,10,11 Previous studies have
demonstrated that BPIFA1 acts as a surfactant,12 can regulate
the amiloride-sensitive epithelial sodium channel, ENaC,13 and
affects mucociliary clearance in the upper airways.14 It has
also been shown to have anti-bacterial roles. For example,
Bpifa1 expression is induced after Mycoplasma infection,
enhancing interleukin-8 production and bacterial clearance.15
BPIFA1 also has a role in defense against Klebsiella pneumo-
niae,16 possibly acting through the modulation of macrophage
function.17 Less is known about any antiviral role of BPIFA1,
although our previous work has shown modulation of BPIFA1
levels after murine g-herpesvirus 68 infection.18
Influenza A virus (IAV) is an enveloped RNA virus of the
Orthomyxovirus genus. Seasonal influenza is a major cause of
respiratory infection resulting in substantial morbidity, mor-
tality, and thus economic burden worldwide.19 Pandemic
influenza strains emerge sporadically as a result of genetic
reassortment and are a substantial global health concern.20
There are vaccines and antiviral drugs to combat influenza.
However, because of rapid virus evolution, vaccines need to be
re-formulated and re-administeredmost years,21 and resistance
against antiviral drugs is emerging.22 It is therefore important to
understand how intrinsic and innate mechanisms modulate
influenza virus infection and how these may be used to develop
novel therapeutic interventions.
The negative-sense, single-stranded genome of IAV com-
prises eight segments of viral RNA, which are separately
encapsidated into ribonucleoprotein particles (RNPs).23
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Infection and entry of IAV into cells involve viral attachment, via
the hemagglutinin glycoprotein that is embedded in the virion
membrane, to cell surface receptors that contain sialic acid
(SA).24 After binding, virus particles enter the cell by receptor-
mediated endocytosis. Fusion of the virus membrane with the
endosomal membrane results in release of RNPs into the
cytoplasm,24,25 which are then imported into the nucleus, where
genome replication and transcription of viral genes take place.26
Understanding the entry process and how the host counters is
critical for uncovering inhibitors with therapeutic potential.
In this study, we used transgenic mouse models combined
with in vitro three-dimensional culture systems to show that
BPIFA1 has a role in the intrinsic defense against IAV infection.
RESULTS
BPIFA1 Expression after IAV Infection
To determine changes in BPIFA1 levels following IAV
infection, C57BL/6J mice were infected intranasally with
103 p.f.u. IAV X-31 (or as controls with ultraviolet-inactivated
virus or mock-infected) and analyzed at time points post
infection (p.i.). IAV X-31 is a mouse-adapted H3N2 strain that
generates a sub-lethal infection.27 It thus models most of the
IAV-associated disease in humans and also allows for analysis
over an extended time course.
First, levels of BPIFA1 in broncho-alveolar lavage were
accurately quantified using (Wes; ProteinSimple, San Jose, CA).
The results (Figure 1) showed that BPIFA1 levels decreased
markedly after infection (100-fold) to a nadir at day 7 p.i. before
returning to a level that was not significantly different to
uninfected mice by day 14 p.i. ultraviolet-inactivated virus did
not affect the levels of BPIFA1 as measured at day 5 p.i.
Next, the pattern and quantity of BPIFA1 staining was
determined by immunohistology. In mock-infected mice,
BPIFA1 was abundant in the epithelium of the trachea and
bronchi (Figure 2a,b, arrows), but present only within
scattered cells in the bronchioles (Figure 2c, arrows) and
absent in the surrounding alveoli (Figure 2c). Following
infection with IAV, a substantial decrease in the number of
BPIFA1-positive cells was observed and confirmed by the
quantitative analysis that showed a 4–8-fold (Po0.05) decrease
in the percentage area stained in the trachea and bronchi,
respectively, to day 7 p.i.; at this point, there were foci of erosion
with reduced cell height, loss of cilia, loss of cellular
polarity, and occasional loss of epithelial cells. Recovery of
levels of BPIFA1 and evidence of epithelial regeneration with
foci ofmultilayered epithelium andmitoses were seen by day 14
p.i. (Figure 2a,b). The intensity of BPIFA1 staining in the
positive areas (i.e., in individual epithelial cells) did not decrease
significantly in the trachea, but in the bronchi a similar pattern
to that of area stained was noted with an initial decrease
followed by a gradual recovery. In contrast, in bronchioles, the
intensity of staining in epithelial cells increased fivefold to day
14 p.i., whereas the number of positive cells (area stained)
increased threefold by day 14 p.i. (Figure 2c).
Mice deficient in BPIFA1 support higher levels of IAV
replication
To determine the role of BPIFA1 in defense against IAV,
BPIFA1-deficient mice (Bpifa1 / ) were generated, as
described in Supplementary Data online and Suppleme-
ntary Figure S1A. Bpifa1 / mice expressed no detectable
BPIFA1 protein in the lungs (Supplementary Figure S1B),
but did not exhibit any morphological changes or altered
distribution of cell types in airways and alveoli (Supplementary
Figure S1C, as described in Supplementary Data).
C57BL/6J and Bpifa1 / mice were infected intranasally
with 103 p.f.u. IAV X-31. The weight of the mice and lung virus
titers were determined over a 28-day period. The results
(Figure 3a,b) showed that wt mice were readily infected with
IAV. They lost weight (maximum 5%; day 6 p.i.) before
recovering. Titers of IAV increased in the lungs, peaking at
106 p.f.u. g 1 tissue on day 5 p.i. Infection in Bpifa1 / mice
followed a similar course. Weight loss was significantly greater
(Po0.01) in Bpifa1 / mice (12% at day 6 p.i.). In addition,
Figure 1 BPIFA1 protein levels in broncho-alveolar lavage (BAL) are
modulated after influenza A virus (IAV) infection. BAL samples were taken
from C57BL/6J mice infected with IAV X-31 at multiple days p.i. The
Simple Western (Wes; ProteinSimple) system was used to quantify
BPIFA1 protein using a rabbit anti-mBPIFA1 primary antibody. Equal
amounts of protein (120 mg as determined by Bicinchoninic acid,
ThermoFisher, Paisley, UK)were loaded per lane. The area of the BPIFA1
peak, in relation to the standard curve, was determined using Compass
software (ProteinSimple). Bars represent mean±s.e.m. (n¼ 4).
Statistically significant differences (one-way analysis of variance with
Tukey’s post hoc analysis) between groups are represented by square
brackets above. *Po0.05; **Po0.01. ND, not determined.
Figure 2 BPIFA1 level in airway epithelia is modulated after influenza A virus (IAV) infection. The lungs were dissected from C57BL6/J mice that were
either mock- or IAV-infected (intranasally with 103 p.f.u. IAV X-31) at multiple days p.i. as indicated. BPIFA1 was detected by immunohistology using
rabbit anti-mBPIFA1, visualized with 3,30-diaminobenzidine, and counterstained with hematoxylin. The percentage area of epithelium stained (left graph
panels) and intensity of staining (right graph panels) in the trachea (a), bronchi (b), and bronchioles (c) were assessed by image analysis. Data are for four
mice per group presented as mean±s.e.m. Statistically significant differences (one-way analysis of variance with Tukey’s post hoc analysis) between
groups are represented by square brackets above. *Po0.05, **Po0.01, ***Po0.001. Micrographs of representative areas at each time point are shown
below the graph panels. Black arrows point to expression of BPIFA1 in respiratory epithelium. Scale Bar¼50 mm (a), 10mm (b), and 20mm (c).
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IAV titers were significant (Po0.05) and at least 1 log10 higher
at all time points. Virus was not detectable in either group at
days 7 and 14 p.i.
To control for potential developmental adaptation in the
knockout (KO) mice, a club cell-specific, tamoxifen (tmx)-
inducible conditional KO mouse strain (Bpifa1loxP; Scgb1a1-
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Figure 3 BPIFA1 influences the infection of mice by influenza A virus (IAV). (a,b). C57BL/6J and Bpifa1 / mice (n¼4 per group) were infected
intranasally with 103 p.f.u. IAV X-31. (a) Mice were weighed daily and the weights represented as a percentage of the starting weight. Data represent the
meanvalue±s.e.m.Asterisks indicate statistical difference (two-way analysis of variance (ANOVA)withBonferroni post test; **Po0.01. (b) Lung tissues
were taken at multiple days p.i. as indicated and virus titer determined by plaque assay. Data represent the mean value±s.e.m. Asterisks indicate
statistical difference (two-way ANOVAwith Bonferroni post test; *Po0.05, ***Po0.001). (c) Bpifa1loxP; Scgb1a1-CreERTMmice were treated with either
carrier (vegetable oil) or carrierþ tamoxifen (tmx) by oral gavage five times as described in the Materials and methods section. Lung tissue (n¼4 per
group) was analyzed by western blotting for BPIFA1. Equal amounts (100 mg) of protein as determined by Bicinchoninic acid (Pierce) were loaded per
lane. The mean (±s.e.m.) levels of BPIFA1 protein were measured by Image J as integrated band intensity. * represents statistical significance (Mann–
WhitneyU-test;Po0.05) BPIFA1 is clearly knocked down in theTamoxifen-treated animals. (d) Tamoxifen-inducible, club cell-specificBPIFA1 knockout
mice (Bpifa1loxP;Scgb1a1-CreERTM) were dosedon5 consecutive daysbygavagewith 0.25mgg1 bodyweight tmxor carrier (vegetable oil). Four days
after the last gavage thesemice, alongwith untreatedBpifa1loxP;Scgb1a1-CreERTMandBpifa1 / mice (n¼ 4 for all groups)were infectedwith IAV for 7
days. The lungs were collected, and virus was titer determined by plaque assay. Data represent the mean value±s.e.m. Asterisks indicate statistical
difference (one-way ANOVA with Tukey’s post hoc analysis; Po0.05).
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CreERTM) was generated, as described in Supplementary Data.
Western blot analysis of lung tissue confirmed a ninefold
knockdown in the level of BPIFA1 in Bpifa1loxP; Scgb1a1-
CreERTMmice after tmx treatment as compared with mice that
were treated with carrier (Figure 3c).
Bpifa1loxP; Scgb1a1-CreERTM mice were treated with either
carrier (vegetable oil) or tmx and, along with untreated
Bpifa1loxP; Scgb1a1-CreERTM and Bpifa1 / mice, were
infected intranasally with IAV. Virus titers in the lungs were
determined at day 7 p.i. The results (Figure 3d) showed that
titers of infectious virus were significantly lower in untreated or
carrier-treated mice than in tmx-treated Bpifa1loxP; Scgb1a1-
CreERTMmice or Bpifa1 / mice. Thus, reduction of BPIFA1
expression using either total or conditional KO of BPIFA1
enabled IAV to be more pathogenic and replicate to higher
titers in the lungs of infected mice.
BPIFA1 limits the initial spread of IAV in vivo
To assess whether BPIFA1 influenced the distribution of IAV
infection, C57BL/6J and Bpifa1 /mice were infected and
IAV-infected cells identified by immunohistology. At day 1 p.i.,
IAV antigen was seen within, and adjacent to, the foci of
necrotic respiratory epithelial cells in the nasal cavity, trachea,
bronchi, and proximal bronchioles of both wt and Bpifa1 /
mice (Supplementary Figure S2, arrows). However, in
Bpifa1 /mice, epithelial cells in the distal bronchioles
were found to be infected, and macrophages in the alveoli
around the infected bronchioles were positive for IAV
(Figure 4, arrows and red arrowheads, respectively). In
contrast, IAV antigen was not observed in distal
bronchioles and alveoli of wt mice. At subsequent days p.i.,
there were no differences in the distribution of IAV antigen
between wt and Bpifa1 / mice.
Thus, in the absence of BPIFA1, IAV infection reached the
distal airways and alveoli earlier during infection.
BPIFA1 restricts IAV infection in normal epithelial cells
Given the differences in viral titer as early as day 1 p.i., we
hypothesized that one function of BPIFA1 could be to influence
directly the infection of epithelial cells. To investigate this,
tracheal cell cultureswere established frommice and cultured at
the air–liquid interface (ALI) to generate well-differentiated
cultures (mouse tracheal epithelial cell, mTEC).28,29 The
validation of these cultures from wt mice is presented in
Supplementary Data and Supplementary Figure S3.
Differentiated mTEC ALI cultures displayed phenotypic
features associated with complex populations of cells
including ciliated cells (b-tubulin and FoxJ1), BPIFA1,
mucin (MUC5B), and SCGB1A1 (CCSP)-expressing cells
that matched with the features of the native rodent airway
epithelium. The cultures from Bpifa1 /mice had similar
levels of ciliogenesis (b-tubulin staining) and mucin (MUC5B
staining) to those from wt counterparts (Supplementary
Figure S4). Quantification of b-tubulin staining showed
that B17% of cells were ciliated in both types of cultures.
In wt cultures, 24% of cells were BPIFA1-positive and were
non-ciliated. Thus, mTEC ALI cultures are highly
representative of mouse airway epithelium and an ideal
model to study the role of BPIFA1 during infection.
mTEC ALI cultures from wt and Bpifa1 / mice were
infected with IAV (0.1 p.f.u. per cell) and infection analyzed by
immunofluorescence. In wt mTEC ALI cells, IAV antigen was
observed predominantly in epithelial cells that did not express
BPIFA1, at both 24 and 48 h p.i. (Figure 5b,c). An increased
number of cells containing IAV NP antigen was seen in
Bpifa1 / mTEC ALI cultures as compared with wt cells at
both time points (Figure 5e,f). Quantification revealed a more
than twofold and nearly twofold higher intracellular IAV NP
load in Bpifa1 / mTEC cultures than in wt mTEC
cultures at 24 and 48 h p.i., respectively (Figure 5g;
Po0.05). There was also a significant increase in infectious
IAV titer in apical wash fluid from Bpifa1 / cells compared
withwt cells (Figure 5h). Thus, BPIFA1 inhibits the infection of
normal (mTECALI) cells by IAV at a stage up to or before early
viral gene expression.
BPIFA1 limits the import of IAV into epithelial cells
Import of virus RNP complexes into the nucleus is one of the
initial steps of the IAV replication cycle. To investigate whether
BPIFA1 influences the early stages of IAV infection, day 14
Figure 4 Influenza A virus (IAV) spreads more rapidly in the absence of
BPIFA1. C57BL/6J and Bpifa1 / mice were infected intranasally with
103 p.f.u. IAV X-31. Lung tissues were collected at 1 day p.i. IAV antigen
was detected by immunohistology using goat anti-IAV, visualized with
3,30-diaminobenzidine, and counterstained with hematoxylin.
Micrographs of representative areas from distal bronchioles and alveoli
four mice are shown. Large arrows, positive epithelial cells. Red
arrowheads, positive macrophages.
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mTEC ALI cultures were infected with IAV. Import of RNP
complexes into the nucleus was then assessed by immuno-
fluorescence analysis using anti-IAV NP. Blocking protein
synthesis with cycloheximide (CHX) was performed to
distinguish imported RNPs from de novo NP production.
The amount of purified virus used was sufficient to enable the
detection of RNP import in 100% of cells in an equivalent assay
performed on MDCK cells (data not shown). The results
(Figure 6a,b) showed that, in the absence of CHX, IAVNPwas
readily observed 4 h after infection in the nuclei of cells fromwt
mice, but, as with the previous experiment, was present in 3.5
more nuclei in cells from Bpifa1 / mice. In the presence of
CHX, RNP complexes were observed in the nuclei of 1% of wt
cells but in a significantly (Po0.05) higher proportion (25 ) of
nuclei in Bpifa1 / cells (Figure 6a, right panels; Figure 6b,c).
Thus, BPIFA1 appreciably decreased the number of cells with
visible accumulation of IAVRNPs after infection, indicating that
it acts at an early stage of the viral life cycle.
BPIFA1 inhibits IAV binding to respiratory epithelial cells
Todeterminewhether BPIFA1affected virus binding,mTECALI
cultures derived from Bpifa1 / and wt mice were incubated
with anAlexa Fluor 488-labeled IAV (IAV-488), and bound virus
was assessed using a confocalmicroscopy. The amount of labeled
virus used was sufficient to enable the detection of binding in
100% of cells in an equivalent assay performed on MDCK cells
(data not shown).wt cells showed IAV binding predominantly to
the surface of Foxj1-positive (ciliated) cells that were negative for
BPIFA1 (Figure 7a). The BPIFA1-positive subpopulation of cells
(non-ciliated; Supplementary Figure S3A,C) presented as focal
Figure 5 BPIFA1 influences the infection of normal mouse tracheal epithelial cell (mTEC) by influenza A virus (IAV). mTEC air–liquid interface (ALI)
cultureswere infectedwith IAVX-31 (0.1 p.f.u. per cell). (a–f) Cellswere processed and stainedwith anti-IAVNP (green) and anti-mBPIFA1 (red), and the
nuclei were counterstained with 40,6-Diamidino-2-phenylindole (blue) and imaged using a confocal microscope. Scale bar¼ 50mm. Micrographs show
representative areas from C57BL/6J mTEC cultures (a–c) and Bpifa1 / mTEC cultures (d–f) at 2, 24, and 48 h p.i. (g) Mean integrated florescence
intensity of IAV nucleoprotein in mTEC ALI shown for three independent biological replicates (±s.e.m.). *Po0.05, one-way analysis of variance
(ANOVA)with Tukey’spost hocanalysis. (h) Titer of IAV in apicalwash.Data presentedasmean±s.e.m.;n¼ 3; *Po0.05, one-wayANOVAwith Tukey’s
post hoc analysis.
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clusters in mTEC ALI cultures (outlined in yellow) and were
predominantly free from IAV binding (Figure 7a). Analysis of
the distribution of a2,3-linked and a2,6-linked SA residues using
the lectins MAA and SNA, respectively, showed that there were
numerous cells with a2,3-linked residues on the cell surface in
both wt and Bpifa1 / cultures (mean n¼ 3; 25% and 22%,
respectively), and that these were on the BPIFA1-negative cells
(Supplementary Figure S5A). The fewa2,6-positive cells present
in the wt and Bpifa1 / cultures (mean n¼ 3; 3% and 5%,
respectively) were mostly BPIFA1-positive (Supplementary
Figure S5B–E). Quantification of bound IAV-488 showed
that the integrated fluorescence intensity of Bpifa1 / cells
was fourfold greater than that from wt cells (Figure 7b,c). Thus,
our data show that IAV bound predominantly to ciliated cells
that were BPIFA1-negative, a2,3-linked SA-positive, and
that the presence of BPIFA1 decreased the binding of IAV to
these cells.
DISCUSSION
BPIFA1 is constitutively expressed and secreted by the airway
epithelium2,6,7,18,30,31 including the submucosal glands.9,28,30,31
However, its precise biological functions remain elusive. Our
studies have uncovered an important role of BPIFA1 in the host
defense against IAV infection. BPIFA1 levels were modulated
after infection, and genetic KO of BPIFA1 led to a higher viral
titer both in vivo and in mTEC ALI cultures. There was also
greater nuclear import of virus RNP complexes and binding of
virus to cells in mTEC cultures lacking BPIFA1.
BPIFA1 has previously been shown to have a defensive role
in M. pneumoniae and K. pneumoniae infection, enhancing
bacterial clearance and inhibiting biofilm formation.15,16 Here
we show, for the first time, that BPIFA1 also has a major role in
the defense against IAV. Notably, higher weight loss was
observed and higher viral titers (41 log10) were recovered from
the lungs of Bpifa1 / mice as compared with wt controls. A
Figure 6 BPIFA1 decreases the nuclear import of influenza A virus (IAV) RNPs into normal mouse tracheal epithelial cell (mTEC). mTEC air–liquid
interface cultures fromwtC57BL/6JorBpifa1 / micewere incubatedwith purified IAVA/PR/8/34 in thepresenceor absenceof cycloheximide (CHX) as
indicated. Cycloheximide blocks protein synthesis and so indicates the import of pre-existing IAVRNP from incoming virus particles. After 4-h incubation
at 37 1C, cultures were processed and stained with anti-IAV NP and counterstained with 40,6-Diamidino-2-phenylindole before visualization using a
confocal microscope. Scale bar¼ 50 mm. (a) Representative micrographs from cultures incubated with IAV in the absence or presence of CHX (b)
micrographs from cultures incubatedwith IAV in the presence of CHX at a highermagnification. (c) Nuclei that were positive for IAVNP in the presence of
cycloheximide were counted at  40 magnification in five fields (one center and four peripheral fields) per sample and presented as a percentage of
positive cells over total cells counted. Themean percentage positive nuclei are shown for three independent biological replicates (±s.e.m.). * represents
statistical significance (one-way analysis of variance with Tukey’s post hoc analysis; Po0.05).
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more rapid spread of IAV to the lung parenchymawas also seen
in Bpifa1 / mice. Specifically, IAV antigen was observed in
the bronchiolar epithelium and alveoli of Bpifa1 / mice but
not of wtmice at 24 h p.i., indicating a possible role of BPIFA1
both in intrinsic and innate defense during early infection and
in the adaptive immune response to IAV. The higher viral titers
in the lungs after conditional knockdown of BPIFA1 in
Scgb1a1-expressing club cells indicate that the observations
seen in the Bpifa1 / mice are not due to developmental
adaptations to the total loss of BPIFA1 expression.
To investigate intrinsic functions of BPIFA1 in the airway
epithelium, we cultured mTEC cells from wt and Bpifa1 /
mice. Although we did not formally rescue the Bpifa1 / cells
using exogenous protein, we controlled for differences between
cultures by performing extensive phenotypic characterization.
Thus, B25% of the cells in wt mTEC had a2,3-linked SA
residues on the surface. These cells were BPIFA1-negative. A
similar proportion of cells (22%) was a2,3 SA-positive in the
Bpifa1 / cultures. Very few cells on wt and Bpifa1 /
cultures were a2,6 SA-positive (3% and 5%, respectively).
Mouse-adapted IAV strains such as those used in this study (X-
31 and PR8) will use both a2,3- and a2,6-linked SA residues
as a receptor.32,33 The similar proportions of cells with a2,3-
and a2,6-linked SA residues between wt and Bpifa1 /
cultures indicate that differences in infection and binding
between wt and Bpifa1 / cultures are due to the absence or
presence of BPIFA1 and are not due to differences in the
number of cells expressing receptors. Infection of mTEC
cultures with IAV paralleled our observations in vivo in that
there was a significantly more rapid spread and higher viral
Figure 7 BPIFA1 restricts binding of influenza A virus (IAV) to normal epithelial cells in mouse tracheal epithelial cell (mTEC) air–liquid interface (ALI)
cultures. mTEC ALI cultures were incubated for 1 h with IAV Alexa-fluor 488-labeled purified IAV A/PR/8/34 (IAV-488), and then fixed with formalin,
stainedwith anti-BPIFA1 and anti-FoxJ1 antibodies, and imaged using a confocal microscope. (a) Representative images of two different fields of day 14
C57BL/6J mTEC ALI culture showing IAV-488 (green) preferentially binding to FoxJ1-positive (white) ciliated cells but not to BPIFA1 (red)-positive cell
populations (circled by yellow dotted line). (b) Micrograph showing IAV-488 binding (green) to the epithelium ofwtC57BL/6 and Bpifa1 / cultures. (c)
Integrated florescence intensity of IAV-488 virus binding to the surfaces of mTEC culture. Images were captured from at least five fields per sample by
confocal microscope at 20,  40, and 60 magnification. The levels of IAV-488 binding to mTEC cell surfaces were measured using Image J as
integrated fluorescence intensity. The mean fluorescent intensity is shown for three independent biological replicates (±s.e.m.). * represents statistical
significance (Mann–Whitney U-test; Po0.05).
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titers in cultures lacking BPIFA1. In linewith the distribution of
a2,3-linked SA receptors, IAVhad a preference for infecting the
BPIFA1-negative population. This confirms a role for BPIFA1
in the intrinsic defense against IAV at the airway epithelium
during the first few days of infection, and shows that the
secreted protein exerts its effects on the epithelial cell surface
rather than solely on the cells that produce it.
Further analysis revealed a much greater import of IAV
RNPs into the nuclei of cells and significantly increased virus
binding in the Bpifa1 / cultures. The fact that only a
percentage of cells were infected in these assays reflects partly
the complex nature of mTEC ALI cultures and where only a
proportion of the cells express the a2,3- and a2,6 SA receptors.
The greater level of inhibition in the RNP import assay
compared with the binding assay suggests an important role of
BPIFA1 in decreasing post-binding entry into cells via
endosomes as well as initial binding of IAV to normal ciliated
epithelial cells in airways. BPIFA1 is secreted and is present in
the periciliary layer,34 so it is easy to envisage how it might be
part of a barrier to IAV infection at the epithelial surface. We
did not characterize whether and how BPIFA1 binds to virus
particles. However, BPIFA1 could either form a non-specific
barrier to IAV engaging with cellular receptors or bind to IAV
and prevent receptor interactions. Gel-forming mucins such as
MUC5AC inhibit virus infection,35 and BPIFA1 has been
shown to associate with the mucus-rich portion of the
pericellular lining fluid.34,36 It has been hypothesized that,
in the case of IAV, this is because of competitive inhibition of
receptors as MUC5AC from mice contains abundant a2,3-
linked SA residues.35 The glycosylation on BPIFA1 contains SA
residues37 and could potentially act by binding to IAV particles
by specific SA–hemagglutinin interactions. Alternatively,
BPIFA1 is a member of the wider tubular lipid-binding
(TULIP) superfamily,38 has a hydrophobic cavity, and binds
several lipids found in mammalian membranes.39 It therefore
has the potential to bind to lipids found in the IAV membrane
and interfere with receptor binding and endosomal fusion.
Further studies are required to determine precisely how
BPIFA1 blocks binding and entry of IAV into normal epithelial
cells.
Previous studies have shown that infection by a number of
pathogens (e.g., P. aeruginosa, S. pneumoniae,M. pneumoniae,
murine g-herpesvirus 68, and IAV) causes an initial transient
increase in secretion of the protein in the first 2–3 h p.i., but this
is followed by a decrease over 2–7 days.15,18,40 Our results
in vivo extend these observations using IAV (Figures 1 and 2).
Decrease in BPIFA1 levels after infection is mediated by
pathogen-associated molecular patterns and interferon-g.40
The IAV strains used here target BPIFA1-negative ciliated
epithelial cells, and BPIFA1 is produced by non-ciliated
epithelial cells. Thus, although IAV induces necrosis of
respiratory epithelial cells, the decrease in BPIFA1 expression
is unlikely the result from direct killing of BPIFA1-expressing
cells. Also, intact respiratory epithelia exhibited decreased
BPIFA1 expression at day 7 p.i. (Figure 2). IAV induces
signaling by a number of pathogen-associated molecular
patterns and so the decrease in BPIFA1 could be due to
this mechanism.41 Inactivated IAV had no effect, suggesting
that active replication is required to mediate a decrease in
BPIFA1 levels. After resolution of the initial infection, BPIFA1
levels returned to pre-infection levels in broncho-alveolar
lavage and the tracheal and bronchial epithelium.
It seems unlikely that BPIFA1 has evolved to have a role in
the defense against IAV alone and thus it is likely that the
protein will influence the pathogenesis of other viruses. It has
been shown to have an inhibitory effect on the replication of
Epstein–Barr virus (a membrane-bound herpesvirus) in
lymphoblastoid cells.42 Downregulation of BPIFA1 expres-
sion43 and polymorphisms in the BPIFA1 gene are also
associated with susceptibility to Epstein–Barr virus-associated
nasopharyngeal carcinoma.44 It will be of interest to determine
whether BPIFA1 affects the pathogenesis of other respiratory
viruses.
These studies have uncovered a significant and unappre-
ciated role of BPIFA1 in host defense against experimental IAV
infections inmurinemodels. It remains to be seen if this protein
is able tomodulate IAV infection in the human host in a similar
manner. The observation of elevated levels of BPIFA1 in nasal
aspirates of childrenwith IAV45 suggests that somemodulation
of the protein does occur during clinical infection and thus is a
potential biomarker. We propose that BPIFA1 may be one
component of the airway surface lining fluid critical to antiviral
host defense. Further studies are needed to determine whether
natural variations in BPIFA1 levels due to genetic polymorph-
isms44 may pre-dispose to more severe IAV-associated disease.
METHODS
Virus. Influenza virus strains A/X-31 (X-31, H3N2) and A/PR/8/34
(PR8, H1N1) were propagated in the allantoic cavity of 9-day-old
embryonated chicken eggs and titered by plaque assay on MDCK
cells.46
Mice. Animal work was reviewed and approved by the local University
of Liverpool Animal Welfare Committee and performed under UK
Home Office Project Licences 40/2483 and 70/8599. Mice were all
specified pathogen-free and maintained under barrier conditions in
individually ventilated cages. Transgenic Bpifa1 /mice were bred at
the University of Liverpool under UKHomeOffice Project Licence 70/
8378. Transgenic mice deficient in BPIFA1 (Bpifa1 / ) and con-
ditional KO were generated (Bpifa1loxP; Scgb1a1-CreERTM), as
described in S1 text and Supplementary Figure S1. Both transgenic
strains were backcrossed 10 generations to C57BL/6J. Wild-type
sex- and age-matched C57BL/6J control mice were purchased from
Charles River (Margate, UK).
Tmx administration. A 20mg/ml tmx stock solution was dissolved in
Mazola corn oil. Tmxwas administered by gavage of 0.25mg g p body
weight to Bpifa1loxP; Scgb1a1-CreERTM adults daily for 5 days. Mice
were then infected with IAV 4 days after the last gavage.
Virus infection of mice. Animals were randomly assigned into
multiple cohorts, anesthetized lightly with KETASET i.m. (Zoetis,
London, UK), and inoculated intranasally with 103 p.f.u. IAV in 50ml
sterile phosphate-buffered saline, or weremock-infected with a similar
volume of allantoic fluid. Mice were killed at variable time points after
infection by cervical dislocation. Tissues were removed immediately
for downstream processing.
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Histology and immunohistology. Histology and immunohistology
were performed on paraformaldehyde-fixed, paraffin-embedded
tissue using the peroxidase anti-peroxidase method, as previously
described.47,48 Primary antibodies used were rabbit anti-mBPIFA16
and goat anti-IAV (Meridian Life Sciences, B65141G).
Quantitative histopathological assessment. The percentage area
and density of 3,30-diaminobenzidine staining within airway epi-
thelium were quantified using whole-slide images scanned and
analyzed using Image-Pro Premier image analysis software version 9.1
(MediaCybernetics, Cambridge, UK). An automated macro and app
(named Trachea.ipp and Airways.ipx, respectively) were developed in
conjunction with MediaCybernetics. They were designed to identify
and outline regions of interest comprising the airway epithelium of the
trachea, bronchi, and bronchioles, while excluding other cells. The
macro and app analyze thresholds of hue, luminosity, and saturation,
which were set relative to the chromogen (DAB) utilized for BPIFA1
localization. These data provided an average density of staining for
each region of interest. The percentage area stained was defined as the
brown area (positive immunostaining) divided by the total brown
areaþ blue area (hematoxylin; negative staining)  100.
Western blotting. Samples were analyzed by 12.5% SDS–PAGE gel
electrophoresis and blotted using rabbit anti-mBPIFA1.6 Band density
was measured using the gel analysis tool of Image J software (NIH,
Bethesda, MD).
Quantitative protein analysis. The Wes system was used to identify
and quantify BPIFA1 protein in broncho-alveolar lavage and lung
samples (ProteinSimple) and rabbit anti-mBPIFA1 as a primary
antibody. The area of BPIFA1 peak, in relation to the standard curve,
was determined and virtual blot-like images were generated using
Compass software (ProteinSimple).
mTEC cultures. mTECs were isolated and differentiated into upper
airway-like epithelium in the ALI culture following previously
described methodology with slight modification.28,29 Whole tracheas
were excised from 6- to 8-week-old mice. Five or six tracheas were
pooled for each evaluation.
Immunofluorescent labeling and confocal imaging. Transwell
membranes were fixed with 10% buffered formalin, and then stained
using primary and secondary antibodies. Primary antibodies usedwere
as follows: rabbit anti-BPIFA1 (1:200),6 rabbit anti-LPLUNC1 (1:100),6
mouse anti-b tubulin (1:100; Sigma Aldrich, Dorset, UK, catalog no.:
T5201),mouse anti-Foxj1 (1:100; eBioscience,Dorset, UK, catalog no.: 14-
9965-82, Clone-2A5), goat anti-SCGB1A1 (1:500; Gift fromBarry Stripp),
rabbit anti-MUC5B(1:100; SantaCruz,Dorset,UK;H-300, catalogno.: sc-
20119), and mouse anti-Influenza A virus NP (anti-IAV NP; 1:200; H16-
L10-4R5 (ATCC HB-65, Manassass, VA)). Secondary antibodies are as
follows (all from Life Technology, OA; 1:200): Alexa Fluor 568 Goat anti-
rabbit antibody (catalog no.: A11011), Alexa Fluor 488 Goat anti-mouse
antibody (catalog no.: A11001), Alexa Fluor 488 Rabbit anti-goat anti-
body (catalog no.: A11078), and Alexa Fluor 633 Goat anti-mouse IgG
(catalog no.: A21050). Samples were mounted on glass slides with
40,6-Diamidino-2-phenylindole Vectashield (Vector Laboratories,
Burlingame, CA, catalog no.: H-1200) and visualized with an
Olympus Fluoview 1000 Confocal microscope (Center Valley, PA).
Virus labeling and IAV-binding assay. IAV A/PR/8/34 was purified
from the allantoic fluid of infected eggs by pelleting through a 30%
sucrose/phosphate-buffered saline cushion followed by banding on
15–60% sucrose/phosphate-buffered saline density gradients. Virus
was then labeled using a green Alexa-fluorophore labeling kit (Life
Technologies, Carlsbad, CA) to yield Alexa Fluor 488-labeled virus
(IAV-488). Unreacted dye was removed by pelleting the virus at
125,000 g. For binding assays, IAV-488was added to the apical surfaces
of day 14mTECALI cultures. After incubation for 1 h and washing off
unbound virus, membranes were immediately fixed with 10% buffered
formalin and co-stained with anti-BPIFA1 and anti-FoxJ1 antibodies.
Images were captured from at least five fields per sample using a
confocal microscope. Integrated fluorescence intensity was measured
using Image J to assess the levels of IAV-488 binding to the cell surface
of mTEC cultures. Three independent experiments were conducted
with cells from three different batches of mice.
Nuclear import assay of IAV virus ribonucleoprotein (virus RNP)
complexes. Apical surfaces of day 14 ALI mTEC cultures were
infected with purified IAV A/PR/8/34. Following infection, cells were
overlaid with DMEM/F-12 media±CHX at a final concentration of
100 mgml 1 (no CHX was the control). Cells were incubated in 5%
CO2 at 37 1C for 4 h, then washed three times with pre-warmedHank’s
Balanced Salt Solution and fixed with 10% buffered formalin as above.
Samples were processed and dual immunostainedwith anti-IAVNP as
described above. Cells displaying nuclear localization of viral RNP
were counted at  40 magnification in five fields (one center and four
peripheral fields) per sample and presented as a percentage of positive
cells over total cells counted. Three independent experiments were
conducted with cells from three biologically different batches of mice.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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